Neulasta is an English word starting with the letter N. With 3 example sentences you'll see exactly how it works in context.
Neulasta in a sentence
Context around Neulasta
- Average sentence length in these examples: 18.3 words
- Position in the sentence: 3 start, 0 middle, 0 end
- Sentence types: 3 statements, 0 questions, 0 exclamations
Corpus analysis for Neulasta
- In this selection, "neulasta" usually appears near the start of the sentence. The average example has 18.3 words, and this corpus slice is mostly made up of statements.
- Around the word, reduces and biosimilar stand out and add context to how "neulasta" is used.
- Recognizable usage signals include also the neulasta biosimilar market and neulasta reduces the. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "neulasta" sits close to words such as aabc, aacr and aacsb, which helps place it inside the broader word index.
Example types with neulasta
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Sales of Neulasta, a bone marrow stimulant, decreased 5% to $1.155 billion. (13 words)
Neulasta reduces the chance of infection due to a low white blood cell count in patients with cancer. (18 words)
Also the Neulasta biosimilar market could potentially become a race-to-the-bottom with a lower priced entry already having joined the market recently. (24 words)
Also the Neulasta biosimilar market could potentially become a race-to-the-bottom with a lower priced entry already having joined the market recently. (24 words)
Neulasta reduces the chance of infection due to a low white blood cell count in patients with cancer. (18 words)
Sales of Neulasta, a bone marrow stimulant, decreased 5% to $1.155 billion. (13 words)
Example sentences (3)
Neulasta reduces the chance of infection due to a low white blood cell count in patients with cancer.
Also the Neulasta biosimilar market could potentially become a race-to-the-bottom with a lower priced entry already having joined the market recently.
Sales of Neulasta, a bone marrow stimulant, decreased 5% to $1.155 billion.